ABL1 Fusion

CI-VAR-00001158Explore in graph →CIViC 1

Curated evidence

Evidence by cancer (464 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 51–100 of 464 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive50
BCR::ABL1 Fusion AND ABL1 D276G	Dasatinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID4358 In an in vitro study, a Ba/F3 cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 2.63nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D276G	Imatinib	Predictive	D	Supports Resistance	2	accepted	EID2663 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.